Quarterly financial reports aren't all that important for pre-revenue biotechs, though they do give investors a chance to hear updated commentary about clinical trials, development plans, and so on. There were no blockbuster announcements from Neurocrine Biosciences (NASDAQ:NBIX) this quarter, but the company now has a clear path to begin the pivotal study of its most valuable 100%-owned asset. I would prefer to see/hear more about the company's efforts to get another drug into clinical development, but I continue to believe that Elagolix and NBI-98854 ('854) support a fair value above $17 today with a vital clinical update due late in the year or early next.
All Clear For Phase III In Tardive Dyskinesia
The most important update...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|